US FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays

The US Food and Drug Administration (FDA) said recently there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Pharma.

Adderall is an FDA-approved prescription drug made of two stimulants amphetamine and dextroamphetamine.

Other manufacturers continue to produce amphetamine-mixed salts, but there is not sufficient supply to continue to meet the U market demand through those producers, the US health regulator said.

According to the FDA’s website, supply recovery for different doses and forms of the drug ranges from October 2022 to March 2023.

“It is possible that some people may encounter a backorder (intermittently) based on timing and high demand, but these are only temporary … and we expect inventory recovery in the coming months,” Teva said.

The company will continue to have challenges supplying Adderall for the next two to three months.

Edits by EP News Bureau